What is Exelixis?
Exelixis, Inc. is dedicated to the discovery, development, and commercialization of innovative medicines aimed at treating difficult-to-treat cancers. The company's portfolio includes CABOMETYX tablets, used for advanced renal cell carcinoma, and COMETRIQ capsules for medullary thyroid cancer. These therapies are derived from cabozantinib, a potent inhibitor targeting key tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Exelixis also offers COTELLIC, an MEK inhibitor for specific advanced melanoma cases, and MINNEBRO, a selective mineralocorticoid receptor blocker for hypertension in Japan. The company's focus on targeted therapies highlights its commitment to advancing precision oncology.
How much funding has Exelixis raised?
Exelixis has raised a total of $118.3M across 1 funding round:
Stock Offering
$118.3M
Stock Issuance/Offering (2000): $118.3M, investors not publicly disclosed
What's next for Exelixis?
With a substantial history of enterprise-level investment, Exelixis is strategically positioned for continued growth and innovation in the competitive oncology landscape. The company's ongoing research and development pipeline, coupled with its existing commercialized products, suggest a trajectory focused on expanding its therapeutic reach and addressing unmet needs in cancer treatment. Future capital infusions, if any, will likely support further clinical trials, global market expansion, and the advancement of novel drug candidates, reinforcing Exelixis's role as a key innovator in the biopharmaceutical industry.
See full Exelixis company page
